Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab)

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement